B+
Bull case
25%
Probability
Target price
$195.00
Analysis reference price unavailable
Analysis 2026-09-08 · RankAlpha Sentiment Codex
A
AgilentANYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
55%
Probability
Target price
$176.17
Analysis reference price unavailable
Analysis 2026-09-08 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$135.00
Analysis reference price unavailable
Analysis 2026-09-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-08
Recent news sentiment (30D)
+0.7
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+87.3
Score
AI commentary
News tone is constructive after the Q3 beat and raised FY2026 outlook, but the packet lacks a verified post-print analyst revision set, options data, and social coverage. The stock remains a positive but monitoring-oriented setup because part of the earnings upside came from tariff refunds [#SEC-8K-2026-08-26].
RankAlpha Sentiment Codex - 2026-09-08
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-26eventQ3 FY2026 beat and raised outlookMedium impact
Agilent reported $1.88 billion of revenue, 7.3% core growth, non-GAAP EPS of $1.62, and raised FY2026 revenue, margin, and EPS guidance. The result exceeded the high end of prior EPS guidance by $0.06 before tariff refunds [#SEC-8K-2026-08-26].
2026-10-31catalystOne-time tariff benefit creates comparison riskMedium impact
Q3 non-GAAP EPS included a $0.06 tariff-refund benefit, while fourth-quarter guidance excludes future tariff refunds. Execution must sustain the raised outlook without repeating that benefit [#SEC-8K-2026-08-26][#PR-EARNINGS-2026-08-31].
2026-10-31catalystBiocare acquisition and pathology expansionMedium impact
The previously announced Biocare Medical acquisition is targeted to close by fiscal Q4 2026 and could improve pathology exposure, mix, and growth if approvals and integration remain on schedule [#PR-2026-03-09].
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-08 • Updated nightlySource: Internal modelMethodology